An Analysis of Bevacizumab or Cetuximab for CRC

Marwan G. Fakih, MD, discussed the implications of the findings from the phase 2 study for patients with microsatellite stable metastatic colorectal cancer without liver metastases.

In this episode of Emerging Experts, Michael LaPelusa, MD, shares his insights, experiences, and passion for cancer research, particularly in the realm of gastrointestinal cancers.

Bevacizumab's survival benefits in CRC patients persist for about 2 years after starting treatment.

In season 4, episode 18 of Targeted Talks, Arvind Dasari, MD, MS, dives into the recent approval of fruquintinib for patients with metastatic colorectal cancer.

A "watch and wait" strategy after total neoadjuvant therapy showed similar outcomes and safety to total mesorectal in stage II/III rectal cancer.

Early palliative care reduces invasive interventions and enhances comfort at EOL for CRC patients, according to real-world study results.